ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements with semaglutide 2.4 mg in people with MASH presented at AASLD 2024 - The Liver Meeting® [Ya...
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. Supportive secondary endpoints showed improvements in liver enzymes, including alanine transaminase ( ALT), aspartate transaminase ( AST), and gamma-glutamyl transferase ( GGT), as well as the Enhanced Liver Fibrosis (ELF) TM test. One in 20 adults in the US are living with metabolic dysfunction-associated steatohepatitis (MASH) , with MASH progressing to cirrhosis in 20% of all cases. PLAINSBORO, N.J. Nov. 19, 2024 /PRNewswire/ -- Novo Nordisk today announced results from part 1 of the ongoing Phase 3 ESSENCE trial. Part 1 evaluated the effect of once-weekly subcutaneous semaglutide 2.4 mg on liver tissue (histology) compared with placebo in people with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3). Results were presented at the 75 th American Associat
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk's Wegovy launches in China, offering obesity drug at a fraction of US prices [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop [Yahoo! Finance]Yahoo! Finance
- Useless Europe is sleepwalking into oblivion [Yahoo! Finance]Yahoo! Finance
- Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/7/24 - Beat
NVO
Sec Filings
- 11/19/24 - Form 6-K
- 11/18/24 - Form 6-K
- 11/14/24 - Form 6-K
- NVO's page on the SEC website